首页> 美国卫生研究院文献>Emerging Infectious Diseases >Clostridiodes difficile in COVID-19 Patients Detroit Michigan USA March–April 2020
【2h】

Clostridiodes difficile in COVID-19 Patients Detroit Michigan USA March–April 2020

机译:Covid-19患者底特律密歇根州美国的ClostrideS艰难梭菌艰难术3月20日

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Sandhu et al. ( ) reported 9 patients who were co-infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and . infection (CDI) can be a co-occurrence or result of antimicrobial drug overuse and is potentially a complication of coronavirus disease (COVID-19). We report a 52-year-old man with hypertension who had fever, respiratory symptoms, abdominal pain, and diarrhea for 3 days. At admission to Saint Michael’s Medical Center (Newark, New Jersey, USA), he had a temperature of 101.8°F but was otherwise hemodynamically stable. He had an elevated absolute lymphocyte count (700 cells/μL), indicating lymphopenia. He tested positive for SARS-CoV-2 RNA by reverse transcription PCR and had elevated inflammatory markers on blood profile. He tested positive for toxin and antigen at admission. He did not use antimicrobial drugs or proton pump inhibitors and had no known contacts with persons with diarrhea. He was mechanically ventilated and received oral vancomycin, intravenous metronidazole, and vasopressors. He died of respiratory failure and septic shock. In comparison to the patients described by Sandhu et al., the patient we report was younger and did not have a history of antimicrobial use.
机译:Sandhu等人。 ()报告了9名患者,被严重急性呼吸综合征冠状病毒2(SARS-COV-2)和。感染(CDI)可以是抗微生物药物过度使用的共同发生或结果,并且可能是冠状病毒疾病(Covid-19)的并发症。我们报告了一名52岁的男子,具有发烧,呼吸系统症状,腹痛和腹泻3天的高血压。在入场前往圣迈克尔的医疗中心(纽瓦克,新泽西州,美国),他的温度为101.8°F,但其他血流动力学稳定。他具有升高的绝对淋巴细胞计数(700个细胞/μl),表明淋巴细胞增长。他通过逆转录PCR测试SARS-COV-2 RNA的阳性,血液剖面上炎症标志物升高。他在入学时测试了毒素和抗原的阳性。他没有使用抗微生物药物或质子泵抑制剂,并且没有与腹泻的人的已知接触。他机械通风并接受口服万古霉素,静脉内甲硝唑和血管加压糖。他死于呼吸衰竭和脓化性休克。与Sandhu等人描述的患者相比,我们报告的患者更年轻,并且没有抗菌用历史。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号